SCHEMBL14403271

SCHEMBL14403271

Cc1ccccc1NS(=O)(=O)Cc1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 3/20 0.55
HPGD P15428 3/20 0.55
GLO1 Q04760 1/20 0.54
MAPK1 P28482 1/20 0.52
PTK2B Q14289 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP9 P14780 1/20 0.52
MMP8 P22894 1/20 0.52
MMP13 P45452 1/20 0.52
KMT2A Q03164 1/20 0.51
ACLY P53396 1/20 0.49
PGR P06401 1/20 0.49
PARP14 Q460N5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23554954 0.84 KEAP1 (0.62) ALDH1A1MAPK1PTK2BKMT2APGR
SCHEMBL10884855 0.82 KDM4E (0.59) ALDH1A1KDM4EHPGDGLO1CA1
SCHEMBL13853042 0.81 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDGLO1MAPK1
SCHEMBL14818627 0.81 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDGLO1MAPK1
SCHEMBL12962542 0.81 PSIP1 (0.63) ALDH1A1PARP14
SCHEMBL23555113 0.81 PARP14 (0.57) ALDH1A1KDM4EHPGDGLO1MAPK1
SCHEMBL14818773 0.81 GLO1 (0.52) ALDH1A1KDM4EHPGDGLO1MAPK1
SCHEMBL13852845 0.80 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDMAPK1PTK2B
SCHEMBL7589006 0.79 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDGLO1MAPK1
SCHEMBL31615866 0.79 HPGD (0.55) ALDH1A1KDM4EHPGDMAPK1PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-21 US disclosed
WO-2013056163-A1 BETA-LACTAMASE INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-04-18 WO disclosed
WO-2007112998-A1 3-UNSUBSTITUTED N-(ARYL- OR HETEROARVL)-PYRAZOLORI [1,5-A]PYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, CYP1A2, COQ8A ALDH1A1 97/4885KDM4E 3756/4885HPGD 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.